CN119700941A - 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 - Google Patents

长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 Download PDF

Info

Publication number
CN119700941A
CN119700941A CN202411943619.6A CN202411943619A CN119700941A CN 119700941 A CN119700941 A CN 119700941A CN 202411943619 A CN202411943619 A CN 202411943619A CN 119700941 A CN119700941 A CN 119700941A
Authority
CN
China
Prior art keywords
conjugate
cells
acting
receptor agonist
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411943619.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·B·基尔科
张平
P·K·布鲁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN119700941A publication Critical patent/CN119700941A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202411943619.6A 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 Pending CN119700941A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US62/506,494 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US62/536,966 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US62/582,186 2017-11-06
US201862648240P 2018-03-26 2018-03-26
US62/648,240 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
CN201880032373.3A CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880032373.3A Division CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Publications (1)

Publication Number Publication Date
CN119700941A true CN119700941A (zh) 2025-03-28

Family

ID=64274790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411943619.6A Pending CN119700941A (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
CN201880032373.3A Active CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880032373.3A Active CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Country Status (10)

Country Link
US (2) US12036283B2 (https=)
EP (1) EP3624827A4 (https=)
JP (3) JP7316222B2 (https=)
KR (2) KR20250057110A (https=)
CN (2) CN119700941A (https=)
AU (2) AU2018270926C1 (https=)
CA (1) CA3060410A1 (https=)
IL (2) IL270634B2 (https=)
MX (2) MX2019013621A (https=)
WO (1) WO2018213341A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020097556A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
EP3946426A4 (en) * 2019-04-05 2023-01-04 Nektar Therapeutics METHOD OF ENHANCING CELLULAR IMMUNOTHERAPY
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
IL288210B2 (en) 2019-05-20 2026-03-01 Cytune Pharma Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
CN117597355A (zh) 2021-06-23 2024-02-23 赛腾制药 白细胞介素15变体
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
IL322075A (en) * 2023-02-14 2025-09-01 Akron Bioproducts Llc Pharmaceutical compositions of interleukin for use in vivo
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1096595A (en) 1993-11-12 1995-05-29 Gilead Sciences, Inc. Thrombin mutants
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
GEP20084487B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
TW200613552A (en) 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
PL2431741T3 (pl) 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2016060996A2 (en) * 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Also Published As

Publication number Publication date
IL270634B1 (en) 2025-02-01
JP7316222B2 (ja) 2023-07-27
KR20200003922A (ko) 2020-01-10
JP2020519676A (ja) 2020-07-02
US20200078467A1 (en) 2020-03-12
MX2019013621A (es) 2020-01-13
CN111093688B (zh) 2025-09-16
IL318018A (en) 2025-02-01
EP3624827A1 (en) 2020-03-25
IL270634A (en) 2019-12-31
AU2018270926B2 (en) 2022-04-07
AU2018270926A1 (en) 2019-11-07
CA3060410A1 (en) 2018-11-22
IL270634B2 (en) 2025-06-01
KR102798243B1 (ko) 2025-04-18
US20240424115A1 (en) 2024-12-26
MX2024009988A (es) 2024-08-27
US12036283B2 (en) 2024-07-16
CN111093688A (zh) 2020-05-01
EP3624827A4 (en) 2021-03-03
AU2022203691A1 (en) 2022-06-16
JP7772733B2 (ja) 2025-11-18
JP2025111770A (ja) 2025-07-30
JP2023082218A (ja) 2023-06-13
AU2022203691B2 (en) 2023-10-12
AU2018270926C1 (en) 2022-10-27
KR20250057110A (ko) 2025-04-28
WO2018213341A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CN111093688B (zh) 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
JP6728055B2 (ja) Ｉｌ−１５部分とポリマーとのコンジュゲート
JP2018154644A (ja) Ｉｌ−２部分とポリマーとのコンジュゲート
JP2010514770A (ja) 解離可能な連結を有する第ｉｘ因子部分−ポリマー共役体
KR20170125839A (ko) Ｉｌ-7 부분 및 중합체의 접합체
IL312646A (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
WO2022020637A1 (en) Il-7 receptor agonist composition and related methods and uses
EA043667B1 (ru) Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения
US20250270273A1 (en) Polymer engineered forms of interferon-gamma and methods of use
HK1235666A1 (en) Conjugates of il-15 and branched polyethylene glycol
HK1235666B (en) Conjugates of il-15 and branched polyethylene glycol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination